BioMedica Inc. Company Profile

05:25 EDT 23rd March 2018 | BioPortfolio

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.Oxford BioMedica’s products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The genes are delivered by the Company’s highly engineered viral systems.
Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes two candidates in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. A Phase III trial in renal cancer with TroVax, the lead cancer immunotherapy candidate, is planned for 2006. In neurotherapy, the Company’s lead product is a gene therapy for Parkinson’s disease, which is expected to enter clinical development in 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.


11622 El Camino Real #100
San Diego
United States of America


Phone: 1 858 677 6500
Fax: 1 858 677 6505

News Articles [22 Associated News Articles listed on BioPortfolio]

Oxford BioMedica set to earn $100 million in deal with Sanofi takeover target

UK gene cell therapy designer Oxford BioMedica’s shares jumped as much as 11.2% to 12.30 pence this…

Oxford BioMedica secures £3m grant from Innovate UK

Innovate UK has awarded Oxford BioMedica a £3m grant to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand.

Oxford BioMedica a secures £3m grant from Innovate UK

Oxford BioMedica has been awarded a £3 million grant by the UK's innovation agency, Innovate UK, to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand.

Oxford BioMedica, Bioverativ sign $100M deal to develop gene therapy material

Bioverativ awarded a $100 million contract to the UK's Oxford BioMedica to develop lentiviral vectors for use in Bioverativ's -More- 

Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy

Oxford BioMedica said today it will partner with Bioverativ to develop and manufacture lentiviral vectors designed to treat hemophilia, through a collaboration that could generate up to $105 million-p...

Oxford Biomedica announces placing to inject £20.5m for expansion

Oxford Biomedica intends to raise approximately £20.5m by way of a conditional placing of ordinary shares to raise money for expansion of bioprocessing facilities, the company said on Friday. The p.....

Oxford BioMedica’s shares shares rise after unveiling US$100mln agreement with Bioverativ

Oxford BioMedica will receive a US$5mln payment upfront and will be eligible to receive various milestone payments potentially worth in excess of US$100mln

Oxford BioMedica wins second $100 million gene therapy contract

LONDON (Reuters) - Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $1...

Drugs and Medications [0 Results]


Clinical Trials [0 Results]


Companies [11 Associated Companies listed on BioPortfolio]

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Acolyte Biomedica Ltd

Acolyte Biomedica Ltd provides rapid diagnostic systems for clinical microbiology. Acolyte's BacLite® platform allows microbial detection in hours instead of days, improving laboratory workflow, redu...

BioMedica Diagnostics Inc.

BioMedica Diagnostics Inc. is a Canadian Medical Devices Company with a dedicated focus on providing Affordable Medical Diagnostic Solutions.The primary targets for our products are the emerging econo...


BIOMEDICA GRUPPE Is a privately owned group of Central European companies, founded in 1978, with head-quarters in Vienna (Austria). Starting as a single distributing company, only it grew to a group o...

More Information about "BioMedica Inc." on BioPortfolio

We have published hundreds of BioMedica Inc. news stories on BioPortfolio along with dozens of BioMedica Inc. Clinical Trials and PubMed Articles about BioMedica Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMedica Inc. Companies in our database. You can also find out about relevant BioMedica Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record